Present BEACON Phase 2 data
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 9 Jun 2023
- Due
- 31 Dec 2023
- Delivered
- December 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“BEACON data from all patients to be presented year-end 2023”
What we found
Evidence strength A What the grades mean
The company presented interim data from the BEACON trial in June and December 2023, fulfilling the commitment to present data by year-end 2023.
-
A Disc Medicine, Inc. 10-Q filed 2024-11-12
“In June and December 2023, we presented interim data from BEACON, a Phase 2 open-label, parallel-dose clinical trial of bitopertin in EPP and XLP patients conducted at sites in Australia.” ✓ confirmed on the page
-
A Disc Medicine, Inc. 8-K filed 2024-03-21
“Presented positive results from the phase 2 BEACON trial at ASH 2023” ✓ confirmed on the page
Market reaction: the shares moved -10.3% against the S&P 500 over the three sessions around the disclosure (20 Mar 2024 to 25 Mar 2024). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- BEACON Phase 2 data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Disc Medicine, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-IRON-002141 · Corrections policy